Buy Uber stock amid robotaxi noise: Oppenheimer

Investing.com
Updated
Mitrade
coverImg
Source: Shutterstock

Investing.com -- Oppenheimer analysts identified Uber Technologies, Inc. (NYSE:UBER) as a top large-cap pick for 2025, emphasizing the current market environment as a buying opportunity.

Despite a recent 23% drop in Uber's share price since earnings—compared to the NASDAQ's 4% gain—the firm maintains an "Outperform" rating with a price target of $85.

Concerns surrounding robotaxis and U.S. ride growth have weighed on Uber's stock, but Oppenheimer views these as overblown.

"US ride growth concerns and Robotaxi have created an attractive buying opportunity," said the firm.

They highlighted Uber's strong fundamentals, including a forecasted 17% revenue and 30% EBITDA compound annual growth rate (CAGR) from 2024 to 2026.

Oppenheimer sees Uber benefiting both in the near and long term.

"UBER should retake lost US Mobility share upon grandfathering higher insurance costs one quarter before LYFT and more aggressive incentives," adds Oppenheimer.

In a future where multiple robotaxi providers coexist, they believe Uber's leading logistics platform positions it to thrive with higher utilization and a lower cost-to-serve model.

While the promise of robotaxis has captured investor attention, Oppenheimer outlined several hurdles, including high fleet costs of $15 billion to $40 billion upfront, vehicle downtime due to maintenance, and infrastructure expansion needs.

"We highlight 15 questions/challenges related to Robotaxi," the note reads, casting doubt on bullish cost assumptions.

Nevertheless, the analysts argue that robotaxis could expand Uber's total addressable market (TAM) by encouraging deeper penetration into consumer car expenses, which currently make up only 2% of Uber's U.S. mobility revenues.

"Even if the ~20% take-rate fell to 10%, the business would be >2x larger, and compares to 13%-15% for online travel," the firm said.

Oppenheimer's $85 price target reflects a valuation of 16x FY26 EBITDA, suggesting significant upside potential from current levels.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
Netflix Q3 Earnings Preview: Double Growth in Revenue and Profit Expected Amid Wall Street's Universal OptimismStreaming giant Netflix is set to release its Q3 2025 financial results after U.S. market close on Tuesday, October 21, with the current market sentiment largely optimistic.
Author  TradingKey
8 hours ago
Streaming giant Netflix is set to release its Q3 2025 financial results after U.S. market close on Tuesday, October 21, with the current market sentiment largely optimistic.
placeholder
Dow Jones futures rise due to easing US-China trade tensions, Fed rate cut betsDow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) regular session on Monday.
Author  FXStreet
9 hours ago
Dow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) regular session on Monday.
placeholder
Japan and Korea Lead Asian Stock Surge — Nikkei 225 Breaks 49,000, KOSPI Tops 3,800Asian equities rallied broadly on Monday, October 20, with Japan and South Korea setting fresh record highs.
Author  TradingKey
10 hours ago
Asian equities rallied broadly on Monday, October 20, with Japan and South Korea setting fresh record highs.
placeholder
Lilly, Novo Nordisk Shares Plummet as Trump Announces Price Cut to OzempicOn Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
Author  TradingKey
Oct 17, Fri
On Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
placeholder
Are European Stocks Peaking? SocGen,Citi Turn Bearish on Q4, U.S. Regional Bank Crisis Adds New RiskA series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.
Author  TradingKey
Oct 17, Fri
A series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.